Search Results

You are looking at 1 - 1 of 1 items for

  • Author: Esin Asan x
  • Refine by access: All content x
Clear All Modify Search
N Dilara Zeybek Departments of, Histology and Embryology, Endocrinology and Metabolism, Medical Biochemistry, Department of Pharmaceutical Technology, Department of Basic Oncology, Faculty of Medicine, Hacettepe University, Sihhiye, Ankara 06100, Turkey

Search for other papers by N Dilara Zeybek in
Google Scholar
PubMed
Close
,
Nese Ersoz Gulcelik Departments of, Histology and Embryology, Endocrinology and Metabolism, Medical Biochemistry, Department of Pharmaceutical Technology, Department of Basic Oncology, Faculty of Medicine, Hacettepe University, Sihhiye, Ankara 06100, Turkey

Search for other papers by Nese Ersoz Gulcelik in
Google Scholar
PubMed
Close
,
F Figen Kaymaz Departments of, Histology and Embryology, Endocrinology and Metabolism, Medical Biochemistry, Department of Pharmaceutical Technology, Department of Basic Oncology, Faculty of Medicine, Hacettepe University, Sihhiye, Ankara 06100, Turkey

Search for other papers by F Figen Kaymaz in
Google Scholar
PubMed
Close
,
Can Sarisozen Departments of, Histology and Embryology, Endocrinology and Metabolism, Medical Biochemistry, Department of Pharmaceutical Technology, Department of Basic Oncology, Faculty of Medicine, Hacettepe University, Sihhiye, Ankara 06100, Turkey

Search for other papers by Can Sarisozen in
Google Scholar
PubMed
Close
,
Imran Vural Departments of, Histology and Embryology, Endocrinology and Metabolism, Medical Biochemistry, Department of Pharmaceutical Technology, Department of Basic Oncology, Faculty of Medicine, Hacettepe University, Sihhiye, Ankara 06100, Turkey

Search for other papers by Imran Vural in
Google Scholar
PubMed
Close
,
Ebru Bodur Departments of, Histology and Embryology, Endocrinology and Metabolism, Medical Biochemistry, Department of Pharmaceutical Technology, Department of Basic Oncology, Faculty of Medicine, Hacettepe University, Sihhiye, Ankara 06100, Turkey

Search for other papers by Ebru Bodur in
Google Scholar
PubMed
Close
,
Hande Canpinar Departments of, Histology and Embryology, Endocrinology and Metabolism, Medical Biochemistry, Department of Pharmaceutical Technology, Department of Basic Oncology, Faculty of Medicine, Hacettepe University, Sihhiye, Ankara 06100, Turkey

Search for other papers by Hande Canpinar in
Google Scholar
PubMed
Close
,
Aydan Usman Departments of, Histology and Embryology, Endocrinology and Metabolism, Medical Biochemistry, Department of Pharmaceutical Technology, Department of Basic Oncology, Faculty of Medicine, Hacettepe University, Sihhiye, Ankara 06100, Turkey

Search for other papers by Aydan Usman in
Google Scholar
PubMed
Close
, and
Esin Asan Departments of, Histology and Embryology, Endocrinology and Metabolism, Medical Biochemistry, Department of Pharmaceutical Technology, Department of Basic Oncology, Faculty of Medicine, Hacettepe University, Sihhiye, Ankara 06100, Turkey

Search for other papers by Esin Asan in
Google Scholar
PubMed
Close

Statins show antiproliferative activity in various cancer cells. The aim of this study was to evaluate the effects of rosuvastatin treatment on papillary thyroid carcinoma. The papillary thyroid carcinoma (B-CPAP) and normal (Nthy-ori 3-1) thyroid cell lines were treated with rosuvastatin at 12.5, 18.5, 25, 50, 100, and 200 μM concentrations. After 48 and 72 h of rosuvastatin treatment, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide, Ki-67 immunolabeling, FACS analysis, electron microscopy, caspase-3, and terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) analysis were performed. Decreased cell viability and G1 phase arrest were detected in papillary thyroid cell line treated with rosuvastatin. Positive immunoreactivity of Ki-67 and dose-dependent increase in S phase on Nthy-ori 3-1 cells were also detected. B-CPAP cells showed intense vacuolisation and autophagosomes with low concentrations and 48 h incubations, while Nthy-ori 3-1 cells showed these changes at higher concentrations. A decrease in the percentage of cells showing autophagy was determined with increasing concentrations of rosuvastatin in B-CPAP cells. Rosuvastatin treatment also caused a dose- and time-dependent increase in caspase-3 activity and apoptotic index by TUNEL assay in B-CPAP cells compared with the Nthy-ori 3-1 cells. Apoptotic cells with nuclear condensation and fragmentation were observed in B-CPAP cell line. Rosuvastatin induced autophagic changes in B-CPAP papillary thyroid cancer cells in lower doses and caused a shift from autophagy to apoptosis. Rosuvastatin may be an alternative treatment for refractory papillary thyroid cancer. Further in vivo studies are necessary to clarify the effects of rosuvastatin in papillary thyroid carcinoma and the clinical implications of rosuvastatin treatment.

Free access